Publications by authors named "Eric Padron"

Claim this Profile
F
Factors affecting treatment decisions for lower-risk myelodysplastic syndromes across practice settings.
Mikkael A Sekeres, Sangeetha Venugopal, Namrata S Chandhok, Justin M Watts, Terrence Bradley, Eric Padron

Leuk Lymphoma· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative assessment of molecular-based prognostic models in CMML.
Luis E Aguirre, Najla Al Ali, Somedeb Ball, Akriti G Jain, David A Sallman, Eric Padron

Blood Neoplasia· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.
David A Sallman, Amy F McLemore, Rami S Komrokji, Hany Elmariah, Andrew T Kuykendall, Eric Padron

Blood Adv· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims.
Rami S Komrokji, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Eric Padron

Clin Lymphoma Myeloma Leuk· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.
Traci L Kruer, Ariel Quintana, Hannah Newman, Meghan Ferrall-Fairbanks, Ling Zhang, Eric Padron

Blood· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.
Somedeb Ball, Akriti G Jain, Najla Al Ali, Luis E Aguirre, Jan Philipp Bewersdorf, Eric Padron

Am J Hematol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Inflammation in CMML Pathobiology and Progression.
Niraj Neupane, Eric Padron

Curr Hematol Malig Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of Indolent Chronic Myelomonocytic Leukemia Phenotypes and Dynamic Features of Disease Progression.
Luis E Aguirre, Somedeb Ball, Akriti Jain, Najla Al Ali, David A Sallman, Eric Padron

Clin Lymphoma Myeloma Leuk· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple TET2 mutations confer additional survival benefit in both myelodysplastic and myeloproliferative chronic myelomonocytic leukemia subtypes.
Clifford M Csizmar, Anuya Natu, Mark Gurney, Saubia Fathima, Ali Khalid A Alsugair, Eric Padron

Leukemia· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematological Response to Frontline Treatment in Lower Risk Myelodysplastic Syndromes (LRMDS) is Associated With Better Overall Survival.
Rami S Komrokji, Muhammad Ammad-Ud-Din, Najla H Al Ali, Zhuoer Xie, Onyee Chan, Eric Padron

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up and combined Phase 2 results of eprenetapopt and azacitidine in patients with mutant MDS/AML.
David A Sallman, Rami S Komrokji, Amy E Dezern, Marie Sebert, Guillermo Garcia-Manero, Eric Padron

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.
Nicola Polverelli, Juan Carlos Hernández-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Eric Padron

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical correlation and prognostic impact of cytogenetic clone size for myelodysplastic syndromes/neoplasm.
Zhuoer Xie, Najla Al Ali, Ling Zhang, Peter Papenhausen, Virginia Olivia Volpe, Eric Padron

Blood Neoplasia· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Precision preclinical modeling to advance cancer treatment.
David H Gutmann, Jesse S Boehm, Elinor K Karlsson, Eric Padron, Mukund Seshadri

J Natl Cancer Inst· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Haploinsufficiency of miR-143 and miR-145 reveal targetable dependencies in resistant del(5q) myelodysplastic neoplasm.
Nadia Gharaee, Joanna Wegrzyn-Woltosz, Jihong Jiang, Vijay Suresh Akhade, Joshua Bridgers, Eric Padron

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum hypoalbuminemia is an independent prognostic factor in Chronic Myelomonocytic Leukemia (CMML).
Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Seongseok Yun, Eric Padron

Leuk Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characteristics and survival outcomes of patients with myelodysplastic syndromes with isolated 11q deletion.
Kensuke Takaoka, Rami Komrokji, Kelly Chien, Guillermo Montalban-Bravo, Julie Braish Salman, Eric Padron

Leuk Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statement.
Uma Borate, Kelly Pugh, Allyson Waller, Rina Li Welkie, Ying Huang, Eric Padron

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to luspatercept can be predicted and improves overall survival in the real-life treatment of LR-MDS.
Angela Consagra, Luca Lanino, Najla H Al Ali, Luis Aguirre, Zhuoer Xie, Eric Padron

Hemasphere· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia.
Akriti G Jain, Virginia O Volpe, Chen Wang, Somedeb Ball, Katherine Tobon, Eric Padron

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study.
Douglas Tremblay, Clifford Csizmar, Courtney D DiNardo, Somedeb Ball, Noa Rippel, Eric Padron

Leukemia· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes-Recommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS]).
Fnu Aakash, Savanah D Gisriel, Amer M Zeidan, John M Bennett, Rafael Bejar, Eric Padron

Mod Pathol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Rami S Komrokji, Luca Lanino, Somedeb Ball, Jan P Bewersdorf, Monia Marchetti, Eric Padron

Lancet Haematol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
Anthony M Hunter, Mrinal M Patnaik, Raphael Itzykson, Ruben Mesa, Chatchada Karanes, Eric Padron

Blood· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study.
Amy E DeZern, Johannes B Goll, Travis L Jensen, Sridhar Nonavinkere Srivatsan, Nancy K Gillis, Eric Padron

Blood Neoplasia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis